ReviewTrends in cardiovascular medicine2017
Cardiovascular disease in patients with rheumatoid arthritis.
Review in Trends in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Cardiovascular risk goal attainment in the United States rheumatologic population.American journal of preventive cardiology · 2026Article
- Cardiovascular rehabilitation in rheumatoid arthritis: evidence and future directions.Rheumatology international · 2025Review
- Neutrophil-to-Lymphocyte Ratio and Fibroblast Growth Factor 21: Their Role in Early Cardiovascular Involvement in Rheumatoid Arthritis.Journal of clinical medicine · 2025Article
- Myocardial infarction in rheumatic diseases.Rheumatology international · 2025Review
- Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis.The Journal of international medical research · 2025Article
- GPIHBP1 increase accounts for rheumatic arthritis-related hypotriglyceridemia by facilitating lipids uptake of white adipose tissues.Arthritis research & therapy · 2025Article
- Anti-arthritic and endothelial protective effects of Derris scandens extract in adjuvant-induced arthritis in rats.PloS one · 2025Article
- Subclinical myocardial changes in rheumatoid arthritis: cardiovascular magnetic resonance evidence of immuno-inflammatory remodeling.Frontiers in cardiovascular medicine · 2025Article
- Research progress on complications of rheumatoid arthritis.Frontiers in immunology · 2025Review
- The Multifaceted Nature of Macrophages in Cardiovascular Disease.Biomedicines · 2024Review
- Article
- Rheumatoid arthritis and cardiovascular complications during delivery: a United States inpatient analysis.European heart journal · 2024Article
- KLF transcription factors in bone diseases.Journal of cellular and molecular medicine · 2024Review
- Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease.Nature communications · 2024Article
- Prediction of Major Adverse Cardiovascular Events by Triglyceride Glucose Index in Predominantly Male Patients with Rheumatoid Arthritis.Reviews in cardiovascular medicine · 2024Article
- JAK-Inhibitors - A Story of Success and Adverse Events.Open access rheumatology : research and reviews · 2024Review
- Rheumatoid Arthritis Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature.Cureus · 2024Article
- Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH/AMPK signaling pathway.International journal of biological sciences · 2024Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is 1.5-2-fold higher than age- and sex-matched individuals from the general population. This excess risk is attributed to the systemic chronic inflammation which is a hallmark of RA. Challenges to optimizing CV risk management in RA include the need for improved methods to predict CV risk, and defining the target risk factor(s) to reduce CV risk. Lessons learned from RA studies can also inform CV risk prevention in the general population, where inflammation also has an important role in the pathogenesis of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.